Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z. Horvat, Paul B. Chapman, Katherine S. Panageas et al.|Journal of Clinical Oncology|2015Cited by 1.1k
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trialSandra P. D’Angelo, Paul Nghiem|Journal for ImmunoTherapy of Cancer|2020Cited by 197
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M. Gounder, Albiruni Ryan Abdul Razak, Alona Zer et al.|Journal of Clinical Oncology|2016Cited by 165
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcomaSandra P. D’Angelo, William D. Tap|Nature Communications|2022Cited by 56